Search results for "pharmacotherapy"

showing 10 items of 283 documents

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

Public Opinion on Psychotropic Drugs: An Analysis of the Factors Influencing Acceptance or Rejection

1997

Widespread negative attitudes and irrational beliefs about psychotropic drugs held by the public affect patients' treatment compliance. This study was an attempt to identify factors influencing people's acceptance or rejection of psychotropic drugs. An opinion poll was taken by a representative group of 2,176 adults in Germany. In addition to their attitudes toward psychotropic and cardiac drugs and their ratings of perceived risks and benefits, they were also asked about their drug knowledge, their fear of losing self-control, and their fundamental political values. Our results show that even for the treatment of severe mental disease, psychotropic drugs generally are not well accepted com…

AdultMaleDrugHealth Knowledge Attitudes Practicemedicine.medical_specialtyAdolescentmedia_common.quotation_subjectAffect (psychology)Public opinionPharmacotherapyPatient Education as TopicGermanymedicineHumansMass MediaPsychiatryHealth EducationBiological Psychiatrymedia_commonPsychotropic Drugsbusiness.industrySocial perceptionMental DisordersPublic healthPoliticsDiscriminant AnalysisCardiovascular AgentsPsychotherapyPsychiatry and Mental healthCardiovascular DiseasesPatient SatisfactionPublic OpinionPatient ComplianceFemaleHealth educationBiological psychiatrybusinessAttitude to HealthThe Journal of Nervous &amp;amp Mental Disease
researchProduct

Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.

2012

Background Here, we assessed the presence of intrahepatic follicular helper T-cells (TFH) in a cohort of consecutive genotype 1 (G1) chronic hepatitis C (CHC) patients comprising non-responders (NRs), relapsers (RRs) or those with sustained virological response (SVR) to pegylated interferon and ribavirin, and tested their relation with the response to antiviral treatment. Methods A total of 78 patients with G1 CHC (30 SVR, 15 RR and 33 NR), comparable for sex, age, viral load and fibrosis were evaluated by immunohistochemistry for liver content of PD1+Bcl6+ TFH cells. The number of TFH cells in the immunostained sections was counted out of five representative high-power microscopic fields (…

AdultMaleGenotypeHepacivirusSettore MED/08 - Anatomia PatologicaAntiviral AgentsPolymorphism Single NucleotideBiomarkers PharmacologicalPolyethylene GlycolsCohort StudiesPharmacotherapyInterferonRibavirinGenotypeFollicular phaseHumansMedicinePharmacology (medical)liver biopsy Interferon-alpha follicular helper T-cellsPharmacologySettore MED/12 - Gastroenterologiabusiness.industryInterleukinsInterferon-alphaT-Lymphocytes Helper-InducerHepatitis CHepatitis C ChronicMiddle AgedViral LoadPrognosismedicine.diseaseImmunohistochemistryRecombinant ProteinsCD4 Lymphocyte CountInfectious DiseasesLiverImmunologyCohortRNA ViralImmunohistochemistryDrug Therapy CombinationFemalehcv immunohistochemistryInterferonsbusinessCohort studymedicine.drug
researchProduct

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

2013

Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 μg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisa…

AdultMaleHBsAgmedicine.medical_specialtyHepatitis B virusTime FactorsAnti-HIV Agentsmedicine.disease_causeGastroenterologyAntiviral AgentsGroup Blaw.inventionPolyethylene GlycolsPharmacotherapyHepatitis B ChronicRandomized controlled triallawPegylated interferonInternal medicinemedicineHumansHepatitis B e AntigensHepatitis B virusbusiness.industryGastroenterologyLamivudineInterferon-alphaAlanine TransaminaseHepatitis BMiddle Agedmedicine.diseaseHepatitis BRecombinant ProteinsTreatment OutcomeLamivudineImmunologyDNA ViralInterferonDrug Therapy CombinationFemaleHepatitis B; Interferonbusinessmedicine.drug
researchProduct

Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study

2010

To compare the management and the virological and serological efficacy of treatments for chronic hepatitis B (CHB) in HIV positive and negative patients.Two hundred and forty-six HIV positive and 205 HIV negative consecutive patients with past or present CHB, seen in October 2008 in participating departments, were included in a multicenter study. All the data were retrospectively collected from the first visit to October 2008 through a standardized questionnaire.Compared to HIV negative patients, HIV positive patients more often presented positive HBeAg (46.4% vs. 32.8%, p=0.01), HBV genotype A (54.8% vs. 17.1%, p0.0001), co-infection with HCV (12.4% vs. 5.9%, p=0.0002) or HDV (12.6% vs. 2.…

AdultMaleHepatitis B virusmedicine.medical_specialtyOrganophosphonatesHIV InfectionsAntiviral AgentsSerologyHepatitis B AntigensHepatitis B ChronicPharmacotherapyAcquired immunodeficiency syndrome (AIDS)Surveys and QuestionnairesInternal medicinemedicineHumansHepatitis B AntibodiesTenofovirSidaRetrospective StudiesHepatologybiologybusiness.industryAdeninevirus diseasesMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseHBeAgLentivirusImmunologyFemaleFranceViral diseasebusinessJournal of Hepatology
researchProduct

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

2010

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as …

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia
researchProduct

Efficacy of naproxen with or without esomeprazole for pain and inflammation in patients after bilateral third molar extractions: a double blinded cro…

2017

Background Using a double-blinded randomized crossover design, this study aimed to evaluate acute postoperative pain management, swelling and trismus in 46 volunteers undergoing extractions of the two lower third molars, in similar positions, at two different appointments who consumed a tablet of either NE (naproxen 500 mg + esomepraz ole 20 mg) or only naproxen (500 mg) every 12 hours for 4 days. Material and Methods Parameters were analyzed: self-reported pain intensity using a visual analog scale (VAS) pre- and postoperative mouth opening; incidence, type and severity of adverse reactions; total quantity consumed of rescue medication; and pre- and postoperative swelling. Results Female v…

AdultMaleMolarNaproxenmedicine.medical_specialtyAdolescentVisual analogue scaleTrismuslaw.inventionEsomeprazoleYoung Adult03 medical and health sciencesCOMPLICAÇÕES PÓS-OPERATÓRIASNaproxen0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawHumansPain ManagementMedicineGeneral DentistryInflammationPain PostoperativeCross-Over Studiesbusiness.industryResearchAnti-Inflammatory Agents Non-SteroidalEsomeprazoleProton Pump Inhibitors:CIENCIAS MÉDICAS [UNESCO]Crossover studySurgeryTreatment OutcomeOtorhinolaryngology030220 oncology & carcinogenesisAnesthesiaUNESCO::CIENCIAS MÉDICASTooth ExtractionDrug Therapy CombinationFemaleMolar ThirdSurgeryOral Surgerymedicine.symptombusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.

2001

Background Controlled trials have firmly established the need for immunosuppressive therapy in autoimmune hepatitis. However, reports about long-term management and prognosis of the disease are scarce. Patients and methods We reviewed the charts of 103 consecutive patients with a well-documented long-term course of autoimmune hepatitis who had been carefully managed over a mean observation period of 95 months (12-405 months). Results Under immunosuppressive therapy 94 patients (91.2%) reached complete remission after a mean treatment duration of 3 +/- 3 months. 28 of the 103 patients (27.2%) were eligible for a trial of treatment withdrawal after a mean treatment duration of 32.2 months (ra…

AdultMalePediatricsmedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentBiopsyPrednisoloneAzathioprineAutoimmune hepatitisLiver transplantationPharmacotherapyLiver Function TestsAzathioprineMedicineHumansChildCyclophosphamideAgedRetrospective StudiesAutoimmune diseaseHepatitismedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLong-Term CareSurgeryHepatitis AutoimmuneLiverDrug Therapy CombinationFemalebusinessLiver function testsImmunosuppressive Agentsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct

Sequential treatment of ADHD in mother and child (AIMAC study): importance of the treatment phases for intervention success in a randomized trial

2018

Abstract Background The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1) before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of the Step 2 PCT on child symptoms after the Step 1 treatment. Methods The analysis included 143 mothers and children (aged 6–12 years) both diagnosed with ADHD. The study design was a two-stage, two-arm parallel group trial (Step 1 treatment group [TG]: …

AdultMalePediatricsmedicine.medical_specialtyEfficacylcsh:RC435-571610Motherslaw.inventionTreatment and control groups03 medical and health sciences0302 clinical medicinePharmacotherapy610 Medical sciences MedicineRandomized controlled trialChild of Impaired ParentslawIntervention (counseling)lcsh:PsychiatryMedicineHumans0501 psychology and cognitive sciencesddc:610ChildChildrenProblem BehaviorPsychiatric Status Rating ScalesPsychotropic Drugsbusiness.industryParent training05 social sciencesTreatment phasesAdult treatmentSequential treatmentCombined Modality Therapy3. Good healthPsychotherapyPsychiatry and Mental healthTreatment OutcomeAttention Deficit Disorder with HyperactivityParent trainingParental psychopathologyFemalebusiness030217 neurology & neurosurgery050104 developmental & child psychologyResearch Article
researchProduct

The Effect of Migraine Prophylaxis on Migraine-Related Resource Use and Productivity

2009

In the US, it is estimated that up to 10% of men and 25% of women, particularly those aged 25-55 years, experience debilitating migraines, such that the condition presents an enormous economic burden for patients, health systems, employers and society. Migraine headache is a particularly prevalent condition associated with major reductions in patients' quality of life. From a payer perspective, the implementation of relevant programmes of migraine prophylaxis is highly desirable. Consistent evidence exists, from several randomized, controlled studies, of the efficacy of amitriptyline, divalproex sodium, propranolol, timolol and topiramate in migraine prophylaxis. Considering resource utiliz…

AdultMaleTopiramatemedicine.medical_specialtyDatabases FactualMigraine DisordersTimololEfficiencyFructosePharmacotherapyCost of IllnessQuality of lifeTopiramatemedicineHumansPharmacology (medical)Amitriptylinebusiness.industrymedicine.diseaseUnited KingdomUnited StatesSurgeryQuality-adjusted life yearPsychiatry and Mental healthRegimenMigraineEmergency medicineCosts and Cost AnalysisQuality of LifeFemaleQuality-Adjusted Life YearsNeurology (clinical)businessmedicine.drugCNS Drugs
researchProduct